Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, February 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 194 articles:
HTML format


 

Single Articles

  1. OH JS, Park DJ, Byeon KH, Ha YS, et al
    Decrease of Preoperative Serum Albumin-to-Globulin Ratio as a Prognostic Indicator after Radical Cystectomy in Patients with Urothelial Bladder Cancer.
    Urol J. 2021 Jan 30. pii: 6350. doi: 10.22037/uj.v16i7.6350.
    PubMed    
    Abstract available

  2. WANG S, Jin S, Shu Q, Wu S, et al
    Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy.
    Pharmaceutics. 2021;13.
    PubMed    
    Abstract available

  3. MAHARJAN DK, Thapa PB
    Laparoscopic Extended Cholecystectomy for Early Gall Bladder Cancer.
    J Nepal Health Res Counc. 2021;18:724-728.
    PubMed    
    Abstract available

  4. BI J, Liu H, Cai Z, Dong W, et al
    Correction for: Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p/RAB27A axis.
    Aging (Albany NY). 2021 Jan 28. pii: 202597. doi: 10.18632/aging.202597.
    PubMed    


  5. NIP L, Salmo E, Surange R, Calleary J, et al
    Mixed histology bladder cancer as a complication of clam ileocystoplasty.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  6. JAZZAR U, Bergerot CD, Shan Y, Wallis CJ, et al
    Use of Psychotropic Drugs Among Older Patients with Bladder Cancer in the United States.
    Psychooncology. 2021 Jan 28. doi: 10.1002/pon.5641.
    PubMed    
    Abstract available

  7. KORNER SK, Dreyer T, Haug ES, Jerlstrom T, et al
    Which data are available in central registries on bladder cancer patients in the five Nordic countries.
    Scand J Urol. 2021 Jan 28:1-7. doi: 10.1080/21681805.2021.1877344.
    PubMed    
    Abstract available

  8. IKEDA J, Ohe C, Yoshida T, Kuroda N, et al
    Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer.
    Pathol Int. 2021 Jan 27. doi: 10.1111/pin.13060.
    PubMed    
    Abstract available

  9. WU J, Xu H, Ji H, Zhai B, et al
    Low Expression of Keratin17 is Related to Poor Prognosis in Bladder Cancer.
    Onco Targets Ther. 2021;14:577-587.
    PubMed    
    Abstract available

  10. WANG W, Qiu J, Qu P, Chen H, et al
    Regulator of cullins-1 (ROC1) negatively regulates the Gli2 regulator SUFU to activate the hedgehog pathway in bladder cancer.
    Cancer Cell Int. 2021;21:75.
    PubMed    
    Abstract available

  11. WANG F, Fan M, Zhou X, Yu Y, et al
    A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer.
    J Exp Clin Cancer Res. 2021;40:44.
    PubMed    
    Abstract available

  12. MINKLER S, Lucien F, Kimber MJ, Sahoo DK, et al
    Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man's Trash Is Another Man's Treasure.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  13. BRUMMELHUIS ISG, Wimper Y, Witjes-van Os HGJM, Arends TJH, et al
    Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  14. QUHAL F, Pradere B, Laukhtina E, Sari Motlagh R, et al
    Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
    World J Urol. 2021 Jan 26. pii: 10.1007/s00345-020-03586.
    PubMed    
    Abstract available

  15. GRUBA N, Stachurski L, Lesner A
    Non-proteasomal Urine Activity in Bladder Cancer.
    Chem Biodivers. 2021 Jan 26. doi: 10.1002/cbdv.202000981.
    PubMed    
    Abstract available

  16. IRUZUBIETA P, Castiella T, Monleon E, Berga C, et al
    Primary cilia presence and implications in bladder cancer progression and invasiveness.
    Histochem Cell Biol. 2021 Jan 25. pii: 10.1007/s00418-021-01965.
    PubMed    
    Abstract available

  17. VARUGHESE M, Treece S, Drinkwater K, Williams M, et al
    Failing to Close the Gap between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy: A Critical Unmet Need.
    Clin Oncol (R Coll Radiol). 2021 Jan 22. pii: S0936-6555(21)00001.
    PubMed    


  18. DONG Y, Hao L, Fang K, Han XX, et al
    A network pharmacology perspective for deciphering potential mechanisms of action of Solanum nigrum L. in bladder cancer.
    BMC Complement Med Ther. 2021;21:45.
    PubMed    
    Abstract available

  19. FRANCOLINI G, Borghesi S, Fersino S, Magli A, et al
    Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the
    Crit Rev Oncol Hematol. 2021 Jan 22:103235.
    PubMed    
    Abstract available

  20. YU X, Li S, Pang M, Du Y, et al
    TSPAN7 Exerts Anti-Tumor Effects in Bladder Cancer Through the PTEN/PI3K/AKT Pathway.
    Front Oncol. 2021;10:613869.
    PubMed    
    Abstract available

  21. LIANG Z, Guo W, Fang S, Zhang Y, et al
    CircRNAs: Emerging Bladder Cancer Biomarkers and Targets.
    Front Oncol. 2021;10:606485.
    PubMed    
    Abstract available

  22. CHEN Y, Liu J, Zhang W, Kadier A, et al
    O-GlcNAcylation Enhances NUSAP1 Stability and Promotes Bladder Cancer Aggressiveness.
    Onco Targets Ther. 2021;14:445-454.
    PubMed    
    Abstract available

  23. GROSSMANN NC, Schuettfort VM, Pradere B, Moschini M, et al
    Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
    Onco Targets Ther. 2021;14:315-324.
    PubMed    
    Abstract available

  24. PACKIAM VT, Labbate CV, Boorjian SA, Tarrell R, et al
    The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis.
    Urol Oncol. 2021 Jan 20. pii: S1078-1439(21)00003.
    PubMed    
    Abstract available

  25. GRIMBERG DC, Dudinec J, Shah A, Inman BA, et al
    Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
    Urol Oncol. 2021 Jan 20. pii: S1078-1439(20)30654.
    PubMed    
    Abstract available

  26. SCHUBACH K, Diocera M, Lauridsen SV
    Bladder Cancer Nursing Updates (EAUN BC SIG and ANZUP BC SIG): Global Updates and Future Joint Directions.
    Semin Oncol Nurs. 2021 Jan 20:151115. doi: 10.1016/j.soncn.2020.151115.
    PubMed    


  27. KOJIMA T
    [.The History of Developing Anticancer Drug for Urothelial Carcinoma and Future Issues].
    Gan To Kagaku Ryoho. 2021;48:41-45.
    PubMed    


  28. KRIEGMAIR MC, Hein S, Schoeb DS, Zappe H, et al
    [Enhanced imaging in urological endoscopy].
    Urologe A. 2021;60:8-18.
    PubMed    
    Abstract available

  29. ERBEN P, Becker C, Tsaur I, Stope MB, et al
    [Molecular subtypes of urothelial carcinoma of the bladder-background and clinical relevance].
    Urologe A. 2021;60:81-88.
    PubMed    
    Abstract available

  30. FALCAO G, Carneiro C, Pinheiro LC
    Bladder paraganglioma: a case report.
    Pan Afr Med J. 2020;36:339.
    PubMed    
    Abstract available

  31. PIERCONTI F, Martini M, Cenci T, Fiorentino V, et al
    Methylation study of the Paris system for reporting urinary (TPS) categories.
    J Clin Pathol. 2021;74:102-105.
    PubMed    
    Abstract available

  32. PRAVEEN B, Varghese J, Krishnamoorthy H, Pillai BS, et al
    A rare case of small cell neuroendocrine tumor of the urinary bladder.
    Indian J Pathol Microbiol. 2020;63:298-300.
    PubMed    
    Abstract available

  33. ABEDINZADEH M, Moghimi M, Dastgheib SA, Maleki H, et al
    Association of NAD (P) H Quinine Oxidoreductase 1 rs1800566 Polymorphism with Bladder and Prostate Cancers - a Systematic Review and Meta-Analysis.
    Klin Onkol. 2020;33:92-100.
    PubMed    
    Abstract available

  34. RZEPKA E, Gilis-Januszewska A, Opalinska M, Sowa-Staszczak A, et al
    Difficulties in the diagnosis and treatment of malignant paraganglioma of the urinary bladder.
    Endokrynol Pol. 2020;71:196-197.
    PubMed    
    Abstract available

  35. HSIEH JJ
    The Gender Issue.
    Clin Genitourin Cancer. 2020;18:77.
    PubMed    


  36. MISTRETTA FA, Cyr SJ, Luzzago S, Mazzone E, et al
    Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes.
    Clin Genitourin Cancer. 2020;18:129-137.
    PubMed    
    Abstract available

  37. KRUGHOFF K, Taylor CE, Snyder PM, Santis WF, et al
    Choriocarcinoma of the Bladder: Case Report and Considerations for Diagnosis.
    Clin Genitourin Cancer. 2020;18:e190-e193.
    PubMed    


  38. AKAND M, Muilwijk T, Van Der Aa F, Gevaert T, et al
    Prognostic score predicts overall survival following complete urinary tract extirpation.
    Scand J Urol. 2020;54:70-79.
    PubMed    
    Abstract available

  39. AZAWI NH, Naeraa SH, Subhi Y, Vasquez JL, et al
    Oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in Denmark.
    Scand J Urol. 2020;54:58-64.
    PubMed    
    Abstract available

  40. HWANG I, Park I, Yoon SK, Lee JL, et al
    Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Clin Genitourin Cancer. 2020;18:e122-e133.
    PubMed    
    Abstract available

  41. MANNAS MP, Lee T, Forbes CM, Hong T, et al
    Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator.
    World J Urol. 2020;38:1215-1220.
    PubMed    
    Abstract available

  42. SYED JS, Abello A, Nguyen J, Lee AJH, et al
    Outcomes for urologic oncology procedures: are there differences between academic and community hospitals?
    World J Urol. 2020;38:1187-1193.
    PubMed    
    Abstract available

  43. BRASSETTI A, Cacciamani G, Anceschi U, Ferriero M, et al
    Long-term oncologic outcomes of robot-assisted radical cystectomy (RARC) with totally intracorporeal urinary diversion (ICUD): a multi-center study.
    World J Urol. 2020;38:837-843.
    PubMed    
    Abstract available

  44. CHOUDHURY A, Porta N, Hall E, Song YP, et al
    Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
    Lancet Oncol. 2021;22:246-255.
    PubMed    
    Abstract available

  45. LABBAN M, Najdi J, Mukherji D, Abou-Kheir W, et al
    Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Cancer Rep (Hoboken). 2021 Feb 4:e1313. doi: 10.1002/cnr2.1313.
    PubMed    
    Abstract available

  46. ZHANG Z, Chen J, Zhu Z, Zhu Z, et al
    CRISPR-Cas13-Mediated Knockdown of lncRNA-GACAT3 Inhibited Cell Proliferation and Motility, and Induced Apoptosis by Increasing p21, Bax, and E-Cadherin Expression in Bladder Cancer.
    Front Mol Biosci. 2021;7:627774.
    PubMed    
    Abstract available

  47. HU J, Yu A, Othmane B, Qiu D, et al
    Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Theranostics. 2021;11:3089-3108.
    PubMed    
    Abstract available

  48. KIM SK, Park SH, Kim YU, Byun YJ, et al
    A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guerin Therapy.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  49. FUJIMOTO T, Sakamoto H, Nakashima M, Imai K, et al
    [Complete Transurethral Resection of Large Non-Muscle-Invasive Bladder Cancer Preoperatively Suspected to Be Muscle-Invasive Disease : A Case Report and Literature Review].
    Hinyokika Kiyo. 2021;67:37-41.
    PubMed    
    Abstract available

  50. SHANG C, Zhu YL, Li YQ, Song GJ, et al
    Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models.
    Invest New Drugs. 2021 Feb 3. pii: 10.1007/s10637-021-01073.
    PubMed    
    Abstract available

  51. HE T, Hu J, Qiu D, Deng H, et al
    Smoking status and pathological response to neoadjuvant chemotherapy among patients with bladder cancer: a pooled analysis.
    Transl Androl Urol. 2021;10:374-383.
    PubMed    
    Abstract available

  52. TIAN J, Sun J, Fu G, Xu Z, et al
    Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?
    Transl Androl Urol. 2021;10:356-373.
    PubMed    
    Abstract available

  53. CAI Z, Jin H, Chen J, Hu J, et al
    Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis.
    Transl Androl Urol. 2021;10:283-291.
    PubMed    
    Abstract available

  54. DU L, Wang X, Yin Y, Zhang Y, et al
    Identification of a potentially functional circRNA-miRNA-mRNA ceRNA regulatory network in bladder cancer by analysis of microarray data.
    Transl Androl Urol. 2021;10:24-36.
    PubMed    
    Abstract available

  55. ESPER RUEDA JA, Carrion Lopez P, Donate Moreno MJ, Herais Raya L, et al
    Usefulness of neoadjuvant chemotherapy in non-metastatic muscle-invasive bladder cancer.
    Actas Urol Esp. 2021 Jan 30. pii: S0210-4806(20)30248.
    PubMed    
    Abstract available

  56. ETXANO J, Rodriguez-Vigil B, Perez F, Beardo P, et al
    Vesical Imaging-Reporting and Data System (VI-RADS(R)): Initial experience in the classification of muscle-invasive bladder cancer.
    Actas Urol Esp. 2021 Jan 30. pii: S0210-4806(20)30239.
    PubMed    
    Abstract available

  57. HE S, Li G, Schatzlein AG, Humphrey PA, et al
    Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis.
    Cell Signal. 2021 Jan 30:109931. doi: 10.1016/j.cellsig.2021.109931.
    PubMed    
    Abstract available

  58. HACKEMER P, Malkiewicz B, Menzel F, Drabik A, et al
    Determinants of survival in patients with bladder cancer undergoing radical cystectomy: The impact of serum creatinine level.
    Adv Clin Exp Med. 2021;30:77-82.
    PubMed    
    Abstract available

  59. OKUYAMA A, Hori M
    Age-specific bladder cancer incidence rate in the world.
    Jpn J Clin Oncol. 2021 Feb 3. pii: 6126763. doi: 10.1093.
    PubMed    


  60. ZHANG X, Zhang J, Zhao W, Dong X, et al
    Long non-coding RNA LINC02446 suppresses the proliferation and metastasis of bladder cancer cells by binding with EIF3G and regulating the mTOR signalling pathway.
    Cancer Gene Ther. 2021 Feb 2. pii: 10.1038/s41417-020-00285.
    PubMed    
    Abstract available

  61. MIYAKE M, Nishimura N, Nakai Y, Fujii T, et al
    Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method.
    Diagnostics (Basel). 2021;11.
    PubMed    
    Abstract available

  62. YAN D, Dong W, He Q, Yang M, et al
    Corrigendum to "Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation": [EBioMedicine 48 (2019) 316-331].
    EBioMedicine. 2021;64:103226.
    PubMed    


  63. ZHAO L, Lian T, Li J, Wei S, et al
    NCR3LG1(B7-H6) is a potential prognostic factor for bladder cancer patients.
    Biomarkers. 2021 Feb 1:1-20. doi: 10.1080/1354750X.2021.1883110.
    PubMed    
    Abstract available

  64. LI G, Zhang X, Guo X, Li Y, et al
    Propofol Inhibits the Proliferation, Migration, and Stem-like Properties of Bladder Cancer Mainly by Suppressing the Hedgehog Pathway.
    Cell Transplant. 2021;30:963689720985113.
    PubMed    
    Abstract available

  65. GRIFFIN LE, Kohrt SE, Rathore A, Kay CD, et al
    Microbial Metabolites of Flavanols in Urine are Associated with Enhanced Anti-Proliferative Activity in Bladder Cancer Cells In Vitro.
    Nutr Cancer. 2021 Feb 1:1-17. doi: 10.1080/01635581.2020.1869277.
    PubMed    
    Abstract available

  66. HAN C, Wang Z, Chen S, Li L, et al
    Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-kappaB Axis.
    Oxid Med Cell Longev. 2021;2021:8851763.
    PubMed    
    Abstract available

  67. KIBARU J, Kotecha P, Iya AM, Russell B, et al
    Scoping review protocol: bladder cancer in Nigeria: what are the gaps in clinical care and research?
    BMJ Open. 2021;11:e041894.
    PubMed    
    Abstract available

  68. SHI H, Xie J, Wang K, Li W, et al
    LINC01451 drives epithelial-mesenchymal transition and progression in bladder cancer cells via LIN28/TGF-beta/Smad pathway.
    Cell Signal. 2021 Jan 28:109932. doi: 10.1016/j.cellsig.2021.109932.
    PubMed    
    Abstract available

  69. PERENNEC T, Supiot S
    [Stereotactic radiotherapy in urologic cancers: Reports from the 3rd international meeting of the Groupe Francophone de Radiotherapie Urologique (GFRU)].
    Bull Cancer. 2021;108:125-128.
    PubMed    
    Abstract available

  70. LARANJO M, Aguiar MC, Pereira NAM, Brites G, et al
    Platinum(II) ring-fused chlorins as efficient theranostic agents: Dyes for tumor-imaging and photodynamic therapy of cancer.
    Eur J Med Chem. 2020;200:112468.
    PubMed    
    Abstract available

  71. IBRAHIM SA, Kulshrestha A, Katara GK, Riehl V, et al
    Cancer-associated V-ATPase induces delayed apoptosis of protumorigenic neutrophils.
    Mol Oncol. 2020;14:590-610.
    PubMed    
    Abstract available

  72. ZHANG C, Shen L, Qi F, Wang J, et al
    Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.
    J Cell Physiol. 2020;235:3849-3863.
    PubMed    
    Abstract available

  73. BOEGEMANN M, Krabbe LM
    Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
    Mini Rev Med Chem. 2020;20:1133-1152.
    PubMed    
    Abstract available

  74. LI C, Su H, Ruan C, Li X, et al
    Keratin 17 knockdown suppressed malignancy and cisplatin tolerance of bladder cancer cells, as well as the activation of AKT and ERK pathway.
    Folia Histochem Cytobiol. 2021 Feb 12. pii: VM/OJS/J/71578.
    PubMed    
    Abstract available

  75. SCHMITZ-DRAGER BJ, Skutetzki A, Rieker RJ, Schwab SA, et al
    Eosinophilic cystitis mimicking bladder cancer-considerations on the management based upon a case report and a review of the literature.
    Virchows Arch. 2021 Feb 12. pii: 10.1007/s00428-021-03049.
    PubMed    
    Abstract available

  76. WOO S, Panebianco V, Narumi Y, Del Giudice F, et al
    Corrigendum to 'Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis' [European Urology Oncology 3 (2020) 306-315].
    Eur Urol Oncol. 2020;3:811.
    PubMed    
    Abstract available

  77. MO XC, Zhang ZT, Song MJ, Zhou ZQ, et al
    Screening and identification of hub genes in bladder cancer by bioinformatics analysis and KIF11 is a potential prognostic biomarker.
    Oncol Lett. 2021;21:205.
    PubMed    
    Abstract available

  78. LEE DH, Jeong JY, Song W
    Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Coh
    Onco Targets Ther. 2021;14:845-855.
    PubMed    
    Abstract available

  79. MURTHY V, Bakshi G, Manjali JJ, Prakash G, et al
    Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy.
    Urol Oncol. 2021 Feb 8. pii: S1078-1439(21)00015.
    PubMed    
    Abstract available

  80. GUAN X, Wei R, Yang R, Lu Z, et al
    Risk and Prognosis of Secondary Bladder Cancer After Radiation Therapy for Rectal Cancer: A Large Population-Based Cohort Study.
    Front Oncol. 2021;10:586401.
    PubMed    
    Abstract available

  81. OTAOLA-ARCA H, Seetharam Bhat KR, Patel VR, Moschovas MC, et al
    Totally intracorporeal robot-assisted urinary diversion for bladder cancer (part 2). Review and detailed characterization of the existing intracorporeal orthotopic ileal neobladder.
    Asian J Urol. 2021;8:63-80.
    PubMed    
    Abstract available

  82. OTAOLA-ARCA H, Coelho R, Patel VR, Orvieto M, et al
    Totally intracorporeal robot-assisted urinary diversion for bladder cancer (Part 1). Review and detailed characterization of ileal conduit and modified Indiana pouch.
    Asian J Urol. 2021;8:50-62.
    PubMed    
    Abstract available

  83. TAN S, Kang Y, Li H, He HQ, et al
    circST6GALNAC6 suppresses bladder cancer metastasis by sponging miR-200a-3p to modulate the STMN1/EMT axis.
    Cell Death Dis. 2021;12:168.
    PubMed    
    Abstract available

  84. PIAO XM, Cha EJ, Yun SJ, Kim WJ, et al
    Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  85. TERRERI S, Mancinelli S, Ferro M, Vitale MC, et al
    Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  86. CLAUSEN TM, Kumar G, Ibsen EK, Orum-Madsen MS, et al
    A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine.
    Cell Death Discov. 2020;6:65.
    PubMed    
    Abstract available

  87. CHENG S, Jiang Z, Xiao J, Guo H, et al
    The prognostic value of six survival-related genes in bladder cancer.
    Cell Death Discov. 2020;6:58.
    PubMed    
    Abstract available

  88. WANG G, Black PC, Goebell PJ, Ji L, et al
    Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.
    Urol Oncol. 2021 Feb 6. pii: S1078-1439(21)00027.
    PubMed    
    Abstract available

  89. LIU YL, Wang XL, Yang XH, Wu XH, et al
    Pooled analysis of Xpert Bladder Cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma.
    World J Surg Oncol. 2021;19:42.
    PubMed    
    Abstract available

  90. WEYERER V, Eckstein M, Strissel PL, Wullweber A, et al
    TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers.
    Genes (Basel). 2021;12.
    PubMed    
    Abstract available

  91. ROSIELLO G, Palumbo C, Deuker M, Stolzenbach LF, et al
    Sex- and age-related differences in the distribution of bladder cancer metastases.
    Jpn J Clin Oncol. 2021 Feb 9. pii: 6131386. doi: 10.1093.
    PubMed    
    Abstract available

  92. ALKASSIS M, Sarkis J, Tayeh GA, Kourie HR, et al
    Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?
    Immunotherapy. 2021 Feb 9. doi: 10.2217/imt-2020-0285.
    PubMed    


  93. YONEDA K, Kamiya N, Utsumi T, Wakai K, et al
    Impact of Lymphovascular Invasion on Prognosis in the Patients with Bladder Cancer-Comparison of Transurethral Resection and Radical Cystectomy.
    Diagnostics (Basel). 2021;11.
    PubMed    
    Abstract available

  94. ZHANG L, Li L, Zhan Y, Wang J, et al
    Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
    Front Oncol. 2021;10:542140.
    PubMed    
    Abstract available

  95. KOTERAZAWA S, Watanabe J, Uemura Y, Uegaki M, et al
    A case of infectious thoracic aortic aneurysm after intravesical Bacillus Calmette-Guerin instillation therapy for a superficial bladder cancer.
    Urol Case Rep. 2021;36:101574.
    PubMed    
    Abstract available

  96. ROSIELLO G, Palumbo C, Deuker M, Stolzenbach LF, et al
    Racial differences in the distribution of bladder cancer metastases: a population-based analysis.
    Cent European J Urol. 2020;73:407-415.
    PubMed    
    Abstract available

  97. YU L, Li Z, Mei H, Li W, et al
    Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro.
    Clin Transl Immunology. 2021;10:e1248.
    PubMed    
    Abstract available

  98. WANG D, Xie D, Bi L, Wang Y, et al
    Benzidine promotes the stemness of bladder cancer stem cells via activation of the Sonic hedgehog pathway.
    Oncol Lett. 2021;21:146.
    PubMed    
    Abstract available

  99. XIE X, Li H, Pan J, Han X, et al
    Knockdown of TRIM26 inhibits the proliferation, migration and invasion of bladder cancer cells through the Akt/GSK3beta/beta-catenin pathway.
    Chem Biol Interact. 2021;337:109366.
    PubMed    
    Abstract available

  100. AHMED SA, Taher MGA, Ali WA, Ebrahem MAES, et al
    Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer.
    Abdom Radiol (NY). 2021 Feb 6. pii: 10.1007/s00261-021-02963.
    PubMed    
    Abstract available

  101. RISTE M, Davda P, Smith EG, Wyllie DH, et al
    Prosthetic hip joint infection by Bacillus Calmette-Guerin therapy following intravesical instillation for bladder cancer identified using whole-genome sequencing: a case report.
    BMC Infect Dis. 2021;21:151.
    PubMed    
    Abstract available

  102. WU Z, Wen Z, Li Z, Yu M, et al
    Identification and prognostic value of a glycolysis-related gene signature in patients with bladder cancer.
    Medicine (Baltimore). 2021;100:e23836.
    PubMed    
    Abstract available

  103. ZHU J, Luo Y, Zhao Y, Kong Y, et al
    circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFbetaR1/VEGF-D signaling.
    Mol Ther. 2021 Feb 3. pii: S1525-0016(21)00065.
    PubMed    
    Abstract available

  104. YANG M, Georgieva MV, Bocharova I, Vembusubramanian M, et al
    The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Retrospective SEER-Medicare Analysis.
    Adv Ther. 2021 Jan 11. pii: 10.1007/s12325-020-01616.
    PubMed    
    Abstract available

  105. BURASCHI S, Morcavallo A, Neill T, Stefanello M, et al
    Discoidin Domain Receptor 1 functionally interacts with the IGF-I system in bladder cancer.
    Matrix Biol Plus. 2020;6-7:100022.
    PubMed    
    Abstract available

  106. ZHANG Q, Lai Q, Wang S, Meng Q, et al
    Clinical Value of Postoperative Neutrophil-to-Lymphocyte Ratio Change as a Detection Marker of Bladder Cancer Recurrence.
    Cancer Manag Res. 2021;13:849-860.
    PubMed    
    Abstract available

  107. JOENSEN UN, Maibom SL, Poulsen AM
    Surgical Management of Muscle Invasive Bladder Cancer: A Review of Current Recommendations.
    Semin Oncol Nurs. 2021 Feb 1:151104. doi: 10.1016/j.soncn.2020.151104.
    PubMed    
    Abstract available

  108. YU YF, Zhou XL, Wang GF, Gu WX, et al
    [Clinicopathological analysis of micropapillary urothelial carcinoma of the bladder].
    Zhonghua Bing Li Xue Za Zhi. 2021;50:125-127.
    PubMed    


  109. LARSSON SC, Mason AM, Kar S, Vithayathil M, et al
    Genetically proxied milk consumption and risk of colorectal, bladder, breast, and prostate cancer: a two-sample Mendelian randomization study.
    BMC Med. 2020;18:370.
    PubMed    
    Abstract available

  110. RAJAIAN S, Murugasen L, Jain D, Chakravarthy Narasimhachar S, et al
    Mullerianosis of the urinary bladder with unilateral complete renal agenesis: a rare coincidental finding causing delayed presentation.
    BMJ Case Rep. 2020;13.
    PubMed    
    Abstract available

  111. HUSSIEN MT, Helmy E, Elsaba TM, Elkady A, et al
    Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.
    Asian Pac J Cancer Prev. 2020;21:1573-1583.
    PubMed    
    Abstract available

  112. PIRES-LUIS AS, Martinek P, Alaghehbandan R, Trpkov K, et al
    Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
    Adv Anat Pathol. 2020;27:303-310.
    PubMed    
    Abstract available

  113. JIA Y, Liu S, Du Y, Yang L, et al
    Intramolecular Coreaction Accelerated Electrochemiluminescence of Polypeptide-Biomineralized Gold Nanoclusters for Targeted Detection of Biomarkers.
    Anal Chem. 2020;92:9179-9187.
    PubMed    
    Abstract available

  114. MASTERSON AN, Liyanage T, Kaimakliotis H, Gholami Derami H, et al
    Bottom-Up Fabrication of Plasmonic Nanoantenna-Based High-throughput Multiplexing Biosensors for Ultrasensitive Detection of microRNAs Directly from Cancer Patients' Plasma.
    Anal Chem. 2020;92:9295-9304.
    PubMed    
    Abstract available

  115. SU Q, Sun Y, Zhang Z, Yang Z, et al
    Identification of Prognostic Immune Genes in Bladder Urothelial Carcinoma.
    Biomed Res Int. 2020;2020:7510120.
    PubMed    
    Abstract available

  116. LIU L, Liu Y, Yan X, Zhou C, et al
    The role of granulocyte colonystimulating factor in breast cancer development: A review.
    Mol Med Rep. 2020;21:2019-2029.
    PubMed    
    Abstract available

  117. ADNAN A, Basu S
    Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to (177)Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement.
    J Nucl Med Technol. 2020;48:148-153.
    PubMed    
    Abstract available

  118. DEL POZO JIMENEZ G, Herranz Amo F, Arranz Arija JA, Rodriguez Fernandez E, et al
    Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy.
    Actas Urol Esp. 2020;44:94-102.
    PubMed    
    Abstract available

  119. SUBIRA-RIOS D, Herranz-Amo F, Moralejo-Garate M, Cano-Velasco J, et al
    Evaluation of laparoscopic approach in radical cystectomy from implementation to consolidation: Internal validation.
    Actas Urol Esp. 2020;44:62-70.
    PubMed    
    Abstract available

  120. METWALLY MI, Zeed NA, Hamed EM, Elshetry ASF, et al
    The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study.
    Eur Radiol. 2021 Feb 19. pii: 10.1007/s00330-021-07765.
    PubMed    
    Abstract available

  121. JAMES M, Kalayarasan R, Gnanasekaran S, Pottakkat B, et al
    Laparoscopic hepatopancreatoduodenectomy for locally advanced gall bladder cancer.
    J Minim Access Surg. 2021 Feb 3. pii: 308673. doi: 10.4103.
    PubMed    
    Abstract available

  122. LI J, Lou Y, Li S, Sheng F, et al
    Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer.
    Front Mol Biosci. 2021;7:598599.
    PubMed    
    Abstract available

  123. HANNA KS
    Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin.
    J Adv Pract Oncol. 2020;11:412-417.
    PubMed    
    Abstract available

  124. KURODA K, Tasaki S, Horiguchi A, Ito K, et al
    Postoperative C-reactive protein-to-albumin ratio predicts poor prognosis in patients with bladder cancer undergoing radial cystectomy.
    Mol Clin Oncol. 2021;14:54.
    PubMed    
    Abstract available

  125. ZHANG R, Jiang M, Lei W, Wang A, et al
    Malignant Acanthosis Nigricans with Recurrent Bladder Cancer: A Case Report and Review of Literature.
    Onco Targets Ther. 2021;14:951-957.
    PubMed    
    Abstract available

  126. HUANG Z, Yan Y, Tang P, Cai J, et al
    TEAD4 as a Prognostic Marker Promotes Cell Migration and Invasion of Urinary Bladder Cancer via EMT.
    Onco Targets Ther. 2021;14:937-949.
    PubMed    
    Abstract available

  127. LIU BB, Ma T, Sun W, Gao WY, et al
    Centromere protein U enhances the progression of bladder cancer by promoting mitochondrial ribosomal protein s28 expression.
    Korean J Physiol Pharmacol. 2021;25:119-129.
    PubMed    
    Abstract available


  128. Expression of Concern: Up-regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating beta-catenin.
    Biosci Rep. 2021;41.
    PubMed    


  129. ZHENG W, Zhang J, Song Q, Xu Y, et al
    Rac Family Small GTPase 3 Correlates with Progression and Poor Prognosis in Bladder Cancer.
    DNA Cell Biol. 2021 Feb 17. doi: 10.1089/dna.2020.5613.
    PubMed    
    Abstract available

  130. OMORI G, Takada K, Murase K, Hayasaka N, et al
    Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer.
    Clin Case Rep. 2020;9:654-659.
    PubMed    
    Abstract available

  131. SHI H, Zhang W, Bi X, Wang D, et al
    Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Cancer Res Treat. 2021 Feb 10. pii: crt.2020.1356. doi: 10.4143/crt.2020.1356.
    PubMed    
    Abstract available

  132. SAVIN Z, Herzberg H, Schreter E, Ben-David R, et al
    Radical cystectomy and perioperative chemotherapy in octogenarians with bladder cancer.
    Can Urol Assoc J. 2021 Feb 12. pii: cuaj.6907. doi: 10.5489/cuaj.6907.
    PubMed    
    Abstract available

  133. ZANGOUEI AS, Hamidi AA, Rahimi HR, Saburi E, et al
    Chemokines as the critical factors during bladder cancer progression: an overview.
    Int Rev Immunol. 2021 Feb 16:1-15. doi: 10.1080/08830185.2021.1877287.
    PubMed    
    Abstract available

  134. TEY J, Ho F, Koh WY, Chia D, et al
    Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis.
    Acta Oncol. 2021 Feb 16:1-13. doi: 10.1080/0284186X.2021.1880025.
    PubMed    
    Abstract available

  135. CHEN M, Zhang R, Lu L, Du J, et al
    Correction for: LncRNA PVT1 accelerates malignant phenotypes of bladder cancer cells by modulating miR-194-5p/BCLAF1 axis as a ceRNA.
    Aging (Albany NY). 2021 Feb 14. pii: 202683. doi: 10.18632/aging.202683.
    PubMed    


  136. RAMALINGAM S, Gunasekaran K, Arora H, Muruganandam M, et al
    Disseminated BCG Infection after intravesical BCG Immunotherapy Of Bladder Cancer.
    QJM. 2021 Feb 15. pii: 6135083. doi: 10.1093.
    PubMed    


  137. PENG M, Xiao D, Bu Y, Long J, et al
    Novel Combination Therapies for the Treatment of Bladder Cancer.
    Front Oncol. 2021;10:539527.
    PubMed    
    Abstract available

  138. LIM CJ, Nguyen PHD, Wasser M, Kumar P, et al
    Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
    Front Immunol. 2021;11:615091.
    PubMed    
    Abstract available

  139. VOSKUILEN CS, van Gennep EJ, Einerhand SMH, Vegt E, et al
    Staging (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer.
    Eur Urol Oncol. 2021 Feb 11. pii: S2588-9311(21)00029.
    PubMed    
    Abstract available

  140. TESCH ME, Pater JA, Vandekerkhove G, Wang G, et al
    Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer.
    NPJ Genom Med. 2020;5:12.
    PubMed    
    Abstract available

  141. MIYAKE M, Nishimura N, Inoue T, Suzuki S, et al
    Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study).
    Trials. 2021;22:136.
    PubMed    
    Abstract available

  142. ROGHMANN F, Breyer J, Kriegmair M, Wezel F, et al
    [Quality assessment of radical cystectomy-opportunities, risks, challenges].
    Urologe A. 2021;60:151-161.
    PubMed    
    Abstract available

  143. SCHULZ GB, Volz Y, Jokisch F, Casuscelli J, et al
    [Enhanced Recovery After Surgery (ERAS(R)) after radical cystectomy-current data].
    Urologe A. 2021;60:162-168.
    PubMed    
    Abstract available

  144. FISCHER ND, Epple S, Wittenmeier E, Betz U, et al
    [Implementation of Enhanced Recovery after Surgery (ERAS(R)) protocol in radical cystectomy at the University Medical Center Mainz].
    Urologe A. 2021;60:169-177.
    PubMed    
    Abstract available

  145. LUZZAGO S, Knipper S, Palumbo C, Rosiello G, et al
    Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder: A Population-based Competing-risks Analysis Across Disease Stages.
    Am J Clin Oncol. 2020;43:880-888.
    PubMed    
    Abstract available

  146. IWATA H, Sassa N, Kato M, Murase Y, et al
    UroVysion((R)) predicts intravesical recurrence after radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: a prospective study.
    Int J Clin Oncol. 2021;26:178-185.
    PubMed    
    Abstract available

  147. SANGOI AR, Chan E, Stohr BA, Kunju LP, et al
    Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin.
    Hum Pathol. 2020;102:54-59.
    PubMed    
    Abstract available

  148. DAI Z, Guo J, Xu J, Liu C, et al
    Target-Driven Nanozyme Growth in TiO2 Nanochannels for Improving Selectivity in Electrochemical Biosensing.
    Anal Chem. 2020;92:10033-10041.
    PubMed    
    Abstract available

  149. KHURRAM R, Khurram A, Chaudhary K
    Index case of synovial metastasis in a patient with transitional cell carcinoma of the bladder.
    BMJ Case Rep. 2020;13.
    PubMed    
    Abstract available

  150. MALTAGLIATI M, Milandri R, Bocchialini T, Graziotti P, et al
    Validation of the effectiveness of a modified Studer orthotopic neobladder in a single center after 3 years of its application.
    Urologia. 2020;87:167-169.
    PubMed    
    Abstract available

  151. DU Y, Xue J, Sun X, Wu D, et al
    Oxygen Vacancy-Enhanced Electrochemiluminescence Sensing Strategy Using Luminol Thermally Encapsulated in Apoferritin as a Transducer for Biomarker Immunoassay.
    Anal Chem. 2020;92:8472-8479.
    PubMed    
    Abstract available

  152. SOUNTOULIDES P, Mutomba WF, Bouras E, Lim J, et al
    How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices.
    Urologia. 2020;87:142-148.
    PubMed    
    Abstract available

  153. RIZZO M, Verzotti E, Di Cosmo G, Cai T, et al
    Perioperative Antimicrobial Prophylaxis for Preventing Infectious Complications After Transurethral Resection of the Bladder: To Use or Not to Use?
    J Endourol. 2020;34:198-202.
    PubMed    
    Abstract available

  154. ECONOMOPOULOU P, Bamias A
    Combination immunotherapy in metastatic urothelial cancer: time for the next step?
    Chin Clin Oncol. 2020;9:23.
    PubMed    


  155. STANGL FP, Thalmann GN
    Continent diversion: five decades of developments and evolution.
    BJU Int. 2020;126:653-660.
    PubMed    
    Abstract available

  156. DEL GIUDICE F, Leonardo C, Simone G, Pecoraro M, et al
    Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the
    BJU Int. 2020;126:610-619.
    PubMed    
    Abstract available

  157. MUILWIJK T, Akand M, Soria F, Giordano A, et al
    The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort.
    BJU Int. 2020;126:704-714.
    PubMed    
    Abstract available

  158. MIYAKE M, Nakai Y, Nishimura N, Ohnishi S, et al
    Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer.
    BJU Int. 2021 Feb 12. doi: 10.1111/bju.15368.
    PubMed    
    Abstract available

  159. PATTARAWAT P, Hong T, Wallace S, Hu Y, et al
    Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
    Br J Cancer. 2020;123:226-239.
    PubMed    
    Abstract available

  160. PRINTZ C
    Liquid biopsy test appears better at detecting bladder cancer than urine cytology.
    Cancer. 2021;127:663.
    PubMed    


  161. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
    A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695).
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-2409.
    PubMed    
    Abstract available

  162. ZHOU Z, Cheng SH, Ding SC, Heung MMS, et al
    Jagged Ends of Urinary Cell-Free DNA: Characterization and Feasibility Assessment in Bladder Cancer Detection.
    Clin Chem. 2021 Feb 19. pii: 6144780. doi: 10.1093.
    PubMed    
    Abstract available

  163. SORIA F, Gontero P
    Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.
    Eur Urol. 2021 Feb 4. pii: S0302-2838(21)00066.
    PubMed    


  164. SIGNORINI C, Maffezzini M
    Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00075.
    PubMed    


  165. LINDGREN MS, Jensen JB
    Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00085.
    PubMed    


  166. CATTO JWF, Downing A, Mason S, Wright P, et al
    Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
    Eur Urol. 2021 Feb 10. pii: S0302-2838(21)00073.
    PubMed    
    Abstract available

  167. KOUTROS S, Decker KL, Baris D, Pardo LA, et al
    Bladder Cancer Risk Associated with Family History of Cancer.
    Int J Cancer. 2021 Jan 27. doi: 10.1002/ijc.33486.
    PubMed    
    Abstract available

  168. BIAN J, Li B, Zeng X, Hu H, et al
    [Corrigendum] Mutation of TGFbeta receptor II facilitates human bladder cancer progression through altered TGFbeta1 signaling pathway.
    Int J Oncol. 2020 Dec 14. doi: 10.3892/ijo.2020.5161.
    PubMed    
    Abstract available

  169. KOJIMA T
    Editorial Comment from Dr Kojima to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
    Int J Urol. 2020;27:1031.
    PubMed    


  170. YOSHIDA T, Matsuda T
    Editorial Comment from Dr Yoshida and Dr Matsuda to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
    Int J Urol. 2020;27:1030-1031.
    PubMed    


  171. KHETRAPAL P
    Editorial Comment to Benefits of robotic cystectomy compared with open cystectomy in an Enhanced Recovery After Surgery program: A propensity-matched analysis.
    Int J Urol. 2020;27:788-789.
    PubMed    


  172. HASSAN AA, Elbendary M, Radwan M, Abo-Farha MO, et al
    Long-term evaluation of modified orthotopic Y-shaped ileal neobladder (Tanta pouch) with left retro-colic chimney.
    Int Urol Nephrol. 2020;52:681-686.
    PubMed    
    Abstract available

  173. MATULAY JT, Li R, Hensley PJ, Brooks NA, et al
    Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.
    J Urol. 2021 Jan 27:101097JU0000000000001633. doi: 10.1097/JU.0000000000001633.
    PubMed    
    Abstract available

  174. YANAGISAWA T, Miki J, Yorozu T, Iwatani K, et al
    Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer.
    J Urol. 2021 Jan 27:101097JU0000000000001630. doi: 10.1097/JU.0000000000001630.
    PubMed    
    Abstract available

  175. WEIN AJ
    Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology.
    J Urol. 2021;205:309-312.
    PubMed    


  176. MEEKS JJ
    Editorial Comment.
    J Urol. 2021;205:107.
    PubMed    


  177. HATAKEYAMA S, Hamano I, Ohyama C
    Editorial Comment.
    J Urol. 2021;205:107.
    PubMed    


  178. ZIBELMAN M, Asghar AM, Parker DC, O'Neill J, et al
    Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.
    J Urol. 2021 Feb 4:101097JU0000000000001602. doi: 10.1097/JU.0000000000001602.
    PubMed    
    Abstract available

  179. FURRER MA, Kiss B, Studer UE, Wuethrich PY, et al
    Seminal Vesical Sparing Cystectomy in Bladder Cancer Patients is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study.
    J Urol. 2021 Feb 3:101097JU0000000000001635. doi: 10.1097/JU.0000000000001635.
    PubMed    
    Abstract available


  180. Erratum: Perceptions of Link between Smoking and Bladder Cancer among United States Adults.
    J Urol. 2021;205:942.
    PubMed    



  181. Erratum: Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage.
    J Urol. 2021;205:942.
    PubMed    


  182. GHOREIFI A, Djaladat H
    Re: Intra-Operative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication RatesDonat SM, Tan KS, Jibara G, Dalbagni G, Arslan Carlon V, Sandhu J J Urol 2020; doi:10.1097/JU.0000000000001329.
    J Urol. 2021;205:335-336.
    PubMed    


  183. HAUTMANN RE, Volkmer B, Egghart G, Frohneberg D, et al
    Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center.
    J Urol. 2021;205:174-182.
    PubMed    
    Abstract available

  184. YAN Q, Zeng P, Zhou X, Zhao X, et al
    RBMX suppresses tumorigenicity and progression of bladder cancer by interacting with the hnRNP A1 protein to regulate PKM alternative splicing.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01666.
    PubMed    
    Abstract available

  185. SUZUKI K, Hinata N, Inoue TA, Nakamura I, et al
    Comparison of the Perioperative and Postoperative Outcomes of Ileal Conduit and Cutaneous Ureterostomy: A Propensity Score-Matched Analysis.
    Urol Int. 2020;104.
    PubMed    
    Abstract available

  186. POLETAJEW S, Krajewski W, Adamowicz J, Kolodziej A, et al
    Management of Intradiverticular Bladder Tumours: A Systematic Review.
    Urol Int. 2020;104.
    PubMed    
    Abstract available

  187. JOKISCH JF, Grimm T, Buchner A, Kretschmer A, et al
    Preoperative Thrombocytosis in Patients Undergoing Radical Cystectomy for Urothelial Cancer of the Bladder: An Independent Prognostic Parameter for an Impaired Oncological Outcome.
    Urol Int. 2020;104.
    PubMed    
    Abstract available

  188. ZHU C, Deng Z, Yuan L, Su J, et al
    Transurethral-Assisted Transumbilical Laparoendoscopic Single-Site Radical Cystectomy: Initial Short-Term Experience.
    Urol Int. 2020;104.
    PubMed    
    Abstract available

  189. SARIER M, Sepin N, Keles Y, Imir L, et al
    Is There any Association between Urothelial Carcinoma of the Bladder and Human Papillomavirus? A Case-Control Study.
    Urol Int. 2020;104.
    PubMed    
    Abstract available

  190. MAKELA R, Arjonen A, Harma V, Rintanen N, et al
    Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
    BMC Cancer. 2020;20:590.
    PubMed    
    Abstract available

  191. LAYTRAGOON LEWIN N, Karlsson JE, Robinsson D, Fagerberg M, et al
    Influence of single nucleotide polymorphisms among cigarette smoking and non-smoking patients with coronary artery disease, urinary bladder cancer and lung cancer.
    PLoS One. 2021;16:e0243084.
    PubMed    
    Abstract available

  192. BESSA A, Rammant E, Enting D, Bryan RT, et al
    The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature.
    PLoS One. 2021;16:e0243136.
    PubMed    
    Abstract available

  193. LIEDBERG F, Hagberg O, Aljabery F, Gardmark T, et al
    Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nation-wide population-based study.
    PLoS One. 2021;16:e0246703.
    PubMed    
    Abstract available

  194. HUANG CY, Wang SC, Chan L, Hsieh TY, et al
    Gender differences in trends of bladder cancer mortality-to-incidence ratios according to health expenditure in 55 countries.
    PLoS One. 2021;16:e0244510.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;